Amyris Inc
NASDAQ:AMRS
Intrinsic Value
Amyris, Inc. engages in the provision of bioscience solutions. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of AMRS.
Amyris Inc's market capitalization is 51.6m USD.
AMRS stock price is 0.14 USD.
AMRS.
AMRS. Open DCF Valuation
AMRS. Open Relative Valuation
AMRS.
AMRS's Revenue has been growing by 17% per year for the last 3 years.
AMRS's Revenue has dropped by 33% over the past 12 months.
AMRS's ROE (Return on Equity) has significantly decreased in the last 3 years from 233% to 149%.
AMRS's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 1% to -118%.
AMRS has positive Gross Profit for the last twelve months.
AMRS has negative Operating Income for the last twelve months.
AMRS has negative Net Income for the last twelve months.
AMRS's ROE (Return on Equity) for the past 12 months is very high and is equal to 149%.
AMRS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -118%.
AMRS's short-term liabilties (471m USD) exceed its short-term assets (244m USD).
AMRS's long-term liabilties (1B USD) exceed its long-term assets (680m USD).
AMRS has negative Free Cash Flow for the last twelve months.
AMRS has positive Net Debt. This means that the company has more debt (754m USD) than cash and short-term investments (11m USD).
AMRS has very high three-year average ROE (Return on Equity): 155%. The company is very efficient at transforming stockholders' equity into net income.
AMRS has negative three-year average ROIC (Return on Invested Capital): -74%. The company is not efficient at using invested capital to generate operating income.
AMRS's D/E (Debt to Equity) is very low and is equal to -1.13.
AMRS's Altman Z-Score is very low and is equal to -8.98.
AMRS doesn't generate enough operating income (-586m USD) to safely cover interest payments on its debt (12m USD).
Fundamental Analysis
Amyris Inc
Balance Sheet Decomposition
Amyris Inc
| Current Assets | 243.7m |
| Cash & Short-Term Investments | 11.2m |
| Receivables | 92.5m |
| Other Current Assets | 139.9m |
| Non-Current Assets | 436m |
| Long-Term Investments | 3m |
| PP&E | 290.5m |
| Intangibles | 95.5m |
| Other Non-Current Assets | 47m |
| Current Liabilities | 470.8m |
| Accounts Payable | 200.1m |
| Accrued Liabilities | 58.2m |
| Other Current Liabilities | 212.5m |
| Non-Current Liabilities | 873.2m |
| Long-Term Debt | 753.9m |
| Other Non-Current Liabilities | 119.4m |
Earnings Waterfall
Amyris Inc
|
Revenue
|
268.2m
USD
|
|
Cost of Revenue
|
-259.2m
USD
|
|
Gross Profit
|
9.1m
USD
|
|
Operating Expenses
|
-594.8m
USD
|
|
Operating Income
|
-585.7m
USD
|
|
Other Expenses
|
-28.8m
USD
|
|
Net Income
|
-614.5m
USD
|
Free Cash Flow Analysis
Amyris Inc
What is Free Cash Flow?
AMRS Profitability Score
Profitability Due Diligence
Amyris Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Amyris Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
AMRS Solvency Score
Solvency Due Diligence
Amyris Inc's solvency score is 21/100. The higher the solvency score, the more solvent the company is.
Score
Amyris Inc's solvency score is 21/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AMRS Price Targets Summary
Amyris Inc
Ownership
AMRS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
AMRS Price
Amyris Inc
| Average Annual Return | 24.8% |
| Standard Deviation of Annual Returns | 90.57% |
| Max Drawdown | -100% |
| Market Capitalization | 51.6m USD |
| Shares Outstanding | 365 603 700 |
| Percentage of Shares Shorted | 23.81% |
Company Profile
Amyris Inc
Country
Industry
Market Cap
Dividend Yield
Description
Amyris, Inc. engages in the provision of bioscience solutions. The company is headquartered in Emeryville, California and currently employs 980 full-time employees. The company went IPO on 2010-09-28. The firm applies its Lab-to-Market biotechnology platform to engineer, manufacture and market high performance, natural and sustainably sourced products using its computational tools, strain construction tools, screening and analytics tools, and advanced lab automation and data integration. The firm's biotechnology platform enables users to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into high-value ingredients that it manufactures at industrial scale. Through the combination of its biotechnology platform and industrial fermentation process, the Company has developed, produced, and commercialized many distinct molecules. The firm is focused on three market areas, Health & Wellness, Clean Beauty and Flavor & Fragrance. Its brands include Biofene, Hemisqualane, Biossance, clean beauty skincare, Pipette, clean baby skincare and Purecane.
You don't have any saved screeners yet
